Press coverage about Selecta Biosciences (NASDAQ:SELB) has been trending somewhat positive on Monday, Accern Sentiment reports. Accern scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Selecta Biosciences earned a daily sentiment score of 0.06 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.6245794155478 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

Shares of Selecta Biosciences (SELB) opened at 15.22 on Monday. The company has a 50-day moving average price of $17.82 and a 200 day moving average price of $15.06. Selecta Biosciences has a 52 week low of $10.27 and a 52 week high of $28.00.

Selecta Biosciences (NASDAQ:SELB) last issued its quarterly earnings results on Friday, August 11th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.86) by $0.01. The business had revenue of $0.03 million for the quarter. Selecta Biosciences had a negative return on equity of 88.31% and a negative net margin of 1,277.76%. Equities analysts anticipate that Selecta Biosciences will post ($3.17) EPS for the current year.

SELB has been the subject of several research analyst reports. Canaccord Genuity set a $25.00 price objective on Selecta Biosciences and gave the stock a “buy” rating in a research note on Saturday, May 13th. Zacks Investment Research raised Selecta Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, ValuEngine raised Selecta Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, June 30th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $26.00.

WARNING: “Selecta Biosciences (SELB) Receives Daily Media Impact Rating of 0.06” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at

In related news, CFO David Siewers sold 6,886 shares of the stock in a transaction that occurred on Monday, June 26th. The stock was sold at an average price of $20.00, for a total transaction of $137,720.00. Following the sale, the chief financial officer now owns 36 shares of the company’s stock, valued at $720. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Lloyd P. Johnston sold 5,959 shares of the firm’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $19.10, for a total value of $113,816.90. Following the completion of the sale, the chief operating officer now directly owns 7,565 shares in the company, valued at approximately $144,491.50. The disclosure for this sale can be found here. Insiders have sold 55,024 shares of company stock worth $1,030,364 in the last three months.

About Selecta Biosciences

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Receive News & Stock Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related stocks with our FREE daily email newsletter.